Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Updated analysis (median follow-up of 33.6 months) of phase 3 trial of Cilta-cel in Rev-refractory myeloma (CARTITUDE-4) shows median PFS not reached with cilta-cel vs 11.8 months in the SOC group, median OS NR vs 37.7 months.”
Title: Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Authors: Hermann Einsele, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels WCJ van de Donk, Surbhi Sidana, Albert Oriol, Yael C. Cohen, Simon J. Harrison, María-Victoria Mateos, Joaquín Martínez-López, Paolo Corradini, Lionel Karlin, Diana Chen, Quanlin Li, Tzu-min Yeh, Katherine Li, Vicki Plaks, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Jordan M. Schecter, Nikoletta Lendvai, Mythili Koneru, Nitin Patel, Erika Florendo, Phoebe Joy Ho, and Rakesh Popat.
You can read the Full Article in The Lancet Oncology.
You can find more posts featuring Robert Orlowski on OncoDaily.
